Xynos Konstantinos 4
4 · Replimune Group, Inc. · Filed Jun 10, 2024
Insider Transaction Report
Form 4
Xynos Konstantinos
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-06-07$7.50/sh−15,881$119,108→ 117,131 total
Footnotes (3)
- [F1]The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on February 13, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.55. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Following the sales reported on this Form 4, the reporting person continues to beneficially own 117,131 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 266,750 shares of the Issuer's common stock, 84,280 of which are exercisable as of the date hereof.